Long-Term Registry Data Reveals Systemic Gaps in Inborn Errors of Immunity Care

Written by The Life Science Feed Editorial Team · Published 28 September 2026 · Edited by Mara Voss

Despite decades of progress in understanding inborn errors of immunity (IEIs), significant disparities persist in patient care across Europe. An extensive 30-year overview of the ESID registry, encompassing over 30,000 patients, reveals concerning heterogeneity in diagnostic practices and access to life-saving therapies, highlighting an urgent need for standardized approaches and policy interventions.

KEY TAKEAWAYS

- The Pivot: The 2021 update to the ESID diagnostic criteria for common variable immunodeficiency (CVID) included more specific immunological parameters, aiming to improve diagnostic accuracy.
- The Data: Over 30 years of ESID registry data, encompassing more than 30,000 patients, reveals significant heterogeneity in Inborn Errors of Immunity (IEI) care across Europe.
- The Action: Clinicians should advocate for expanded newborn screening programs for IEIs and ensure timely referrals to specialized immunology centers to mitigate diagnostic delays and improve patient outcomes.

The ESID Registry: A 30-Year Overview

The ESID registry represents a massive undertaking, accumulating data from centers across Europe and beyond. Thirty years of data, over 30,000 patients - what does it tell us? While the registry provides a comprehensive overview of IEI manifestations, treatment strategies, and outcomes, it also exposes significant heterogeneity in care. Are all centers adhering to the same diagnostic criteria? Are all patients receiving equal access to potentially life-saving therapies? The devil, as always, is in the details. We need to look beyond the broad statistics and examine the specific factors that contribute to disparities in care. Is it geographic location? Socioeconomic status? Lack of awareness among primary care physicians? These are the questions that policy makers need to address.

Guideline Comparison: Where Do We Stand?

Several international guidelines address the diagnosis and management of IEIs, including those from ESID, the Primary Immunodeficiency Treatment Consortium (PIDTC), and the American Academy of Allergy, Asthma & Immunology (AAAAI). While these guidelines provide a framework for clinical decision-making, the ESID registry data reveals that adherence to these guidelines is far from uniform. For example, the guidelines emphasize early genetic screening for specific IEIs, yet diagnostic delays remain a significant problem. Is it a lack of awareness, or is it simply the cost barrier that stands in the way? How can we ensure that these guidelines are translated into consistent clinical practice?

The 2021 update to the ESID diagnostic criteria for common variable immunodeficiency (CVID) included more specific immunological parameters. Did this actually improve the speed and accuracy of CVID diagnosis in practice, or simply add more hurdles to jump?

Study Limitations: The Catch

Let's be clear - registry data, while valuable, isn't perfect. The ESID registry relies on voluntary data submission, which introduces the potential for selection bias. Centers with more resources and a greater interest in IEIs are more likely to participate, potentially skewing the results. Furthermore, the data is observational, making it difficult to establish causal relationships. We can observe correlations between treatment strategies and outcomes, but we can't definitively prove that one caused the other. And of course, there are the inevitable inconsistencies in data collection and reporting across different centers. Standardizing data collection protocols is an ongoing challenge. Who pays for the audits to ensure accuracy?

Economic Value of Early Intervention

The economic burden of IEIs is substantial, encompassing diagnostic testing, treatment costs, and the management of complications like recurrent infections and autoimmune disorders. Delayed diagnoses exacerbate this burden, leading to increased healthcare utilization and reduced quality of life. Early intervention, such as prophylactic immunoglobulin therapy or hematopoietic stem cell transplantation (HSCT), can prevent complications and improve long-term outcomes, ultimately reducing healthcare costs. A cost-effectiveness analysis of newborn screening for severe combined immunodeficiency (SCID) demonstrated that early detection and treatment were associated with significant cost savings compared to delayed diagnosis. But who is going to fund these interventions? Are insurance companies willing to invest in preventive care, or will they continue to prioritize short-term cost savings over long-term health benefits?

Actionable Policy Recommendations

Based on the ESID registry data and other evidence, several policy recommendations can be made:

• Expand newborn screening programs to include a wider range of IEIs, particularly those for which effective treatments are available.

• Improve access to specialized immunology centers, ensuring that patients receive timely and accurate diagnoses.

• Establish national registries for IEIs, promoting data sharing and collaboration among centers.

• Ensure reimbursement for essential therapies, such as immunoglobulin therapy and HSCT, regardless of a patient's socioeconomic status.

• Raise awareness among primary care physicians about the signs and symptoms of IEIs.

These steps are not just about improving patient outcomes; they're about creating a more efficient and equitable healthcare system. The ESID registry has provided us with the data; it’s now up to policymakers to act.

CLINICAL IMPLICATIONS

The most striking consequence of the ESID registry data is the undeniable heterogeneity in care for Inborn Errors of Immunity (IEIs) across Europe. This isn't just an academic concern. It means real patients are facing delayed diagnoses and unequal access to life-saving treatments like immunoglobulin therapy or hematopoietic stem cell transplantation. For clinicians, this underscores the urgent need to scrutinize local practices against established guidelines from bodies like ESID and the AAAAI. Are we truly providing the best possible care, or are systemic barriers hindering our efforts?

Industry must also take note. The economic burden of delayed IEI diagnosis is substantial, driven by complications and increased healthcare utilization. Companies developing innovative diagnostics and therapies for IEIs should advocate for broader newborn screening programs and improved access to specialized immunology centers. A 2018 study by Germain et al. on SCID screening demonstrated significant cost savings with early detection. This evidence should empower industry to champion preventive care, even if it means challenging traditional insurance models that prioritize short-term savings over long-term patient benefit.

For patients, these findings are a call to action. They highlight the importance of advocating for timely and accurate diagnoses, and for access to specialized care. While the ESID registry is invaluable, its reliance on voluntary data submission means the full picture may be even more challenging. We need national registries with standardized data collection protocols to truly understand and address these disparities. This requires sustained funding, robust audit mechanisms, and a commitment from all stakeholders to prioritize patient outcomes over institutional convenience.

FOLLOW THE LIFE SCIENCE FEED